Cargando…

Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF

BACKGROUND: Patients with AF often have multimorbidity (the presence of ≥2 concomitant chronic conditions). OBJECTIVE: To describe baseline characteristics, patterns of antithrombotic therapy, and factors associated with oral anticoagulant (OAC) prescription in patients with AF and ≥2 concomitant, c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kozieł, Monika, Teutsch, Christine, Halperin, Jonathan L., Rothman, Kenneth J., Diener, Hans-Christoph, Ma, Chang-Sheng, Marler, Sabrina, Lu, Shihai, Gurusamy, Venkatesh K., Huisman, Menno V., Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046191/ https://www.ncbi.nlm.nih.gov/pubmed/33852611 http://dx.doi.org/10.1371/journal.pone.0249524

Ejemplares similares

Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
por: Beier, Lea, et al.
Publicado: (2022)

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
por: Mazurek, Michał, et al.
Publicado: (2017)

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
por: Huisman, Menno V., et al.
Publicado: (2022)

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020)

Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort
por: Huisman, Menno V., et al.
Publicado: (2016)

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
por: Kozieł, Monika, et al.
Publicado: (2020)

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
por: Dubner, Sergio J., et al.
Publicado: (2020)

Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF
por: van der Wall, Sake J., et al.
Publicado: (2021)

Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry
por: Dubner, Sergio, et al.
Publicado: (2020)

Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry: Trends in antithrombotic therapy use in China
por: Liu, Xiaoxia, et al.
Publicado: (2023)

Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program
por: McIntyre, William F., et al.
Publicado: (2018)

Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program
por: Azar, Rabih R., et al.
Publicado: (2021)

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world
por: Kozieł, Monika, et al.
Publicado: (2021)

Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA‐AF Phase III Registry
por: Bayer, Valentina, et al.
Publicado: (2022)

Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA‐AF Registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2022)

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2023)

Comorbidities and Antithrombotic Treatment Pattern in Patients With Atrial Fibrillation
por: Bang, Oh Young, et al.
Publicado: (2022)

The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2022)

Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention
por: Huisman, M. V.
Publicado: (2021)

Treatment implications of renal disease in patients with atrial fibrillation: The BALKAN‐AF survey
por: Kozieł, Monika, et al.
Publicado: (2020)

Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in Turkey: Inferences from GARFIELD-AF registry
por: Sayın, Begüm Yetiş, et al.
Publicado: (2019)

Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation
por: Tzeis, Stylianos, et al.
Publicado: (2020)

Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey
por: Kozieł, Monika, et al.
Publicado: (2020)

Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey
por: Kozieł, Monika, et al.
Publicado: (2019)

Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: Findings From the CONNECT AF+PCI Study
por: Valle, Felipe H., et al.
Publicado: (2021)

Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation
por: Chu, Gordon, et al.
Publicado: (2020)

Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry
por: Pope, Marita Knudsen, et al.
Publicado: (2021)

Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand’s COOL-AF registry
por: Winijkul, Arjbordin, et al.
Publicado: (2021)

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
por: DeVore, Adam D., et al.
Publicado: (2016)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

Antithrombotic management of patients with atrial fibrillation—Dutch anticoagulant initiatives anno 2020
por: Chu, G., et al.
Publicado: (2020)

Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry
por: Apenteng, Patricia N, et al.
Publicado: (2018)

Indonesian registry on atrial fibrillation (OneAF)
por: Raharjo, Sunu Budhi, et al.
Publicado: (2021)

Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study
por: Bano, Arjola, et al.
Publicado: (2021)

Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF
por: Camm, Alan John, et al.
Publicado: (2023)

Gloria
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_8sjimnq7qi44oqq9gb5ur9virn